Dupixent (Dupilumab)
Dupixent (Dupilumab)
Dupilumab
Product information
Dupixent is an injectable medication used to treat conditions such as eczema (atopic dermatitis), asthma, and chronic sinusitis with nasal polyps. It works by targeting specific pathways in the immune system to reduce inflammation and improve symptoms. Buying Dupixent from Canada can help patients access this effective treatment at a lower cost.
RX Required
Product options
Dupixent – Drug Information, How to Inject, Side Effects, and Savings for Americans
Dupixent (dupilumab) is a prescription injectable biologic medicine used to treat several inflammatory conditions that are driven by overactive “type 2” inflammation. For many Americans, the biggest challenge is cost. U.S. pricing for biologics can be extremely high, especially if your insurance has a large deductible, limited coverage, or restrictive prior authorizations.
That’s why many Americans look to Canada for cheaper brand-name medications. Over The Border Meds is a Canadian prescription referral service that helps eligible U.S. patients access medications like Dupixent from Canada with a valid prescription. If you’re searching online for “buy Dupixent from Canada” or “cheaper Dupixent for Americans,” the sections below will walk through how Dupixent works, who it’s for, dosing basics, how to inject it safely, and what side effects to watch for.
What Dupixent Is Used For
Dupixent is used in addition to other treatments (when appropriate) for several conditions. Depending on your diagnosis, your prescriber may use Dupixent to help control symptoms and reduce flares.
- Atopic dermatitis (eczema)
- Asthma (including severe eosinophilic asthma and asthma requiring oral corticosteroids in some patients)
- Chronic obstructive pulmonary disease (COPD) in adults with raised eosinophil levels, used as add-on maintenance therapy
- Chronic rhinosinusitis with nasal polyposis (CRSwNP) as add-on therapy with intranasal corticosteroids for severe disease not adequately controlled with oral steroids and/or surgery
- Eosinophilic esophagitis (EoE) in patients aged 1 year and older weighing at least 15 kg
- Prurigo nodularis (PN) in adults with moderate-to-severe disease not adequately controlled with prescription topical therapy
- Chronic spontaneous urticaria (CSU) in patients 12 years of age and older whose symptoms are not adequately controlled with H1 antihistamines
How Dupixent Works
Dupixent contains dupilumab, a monoclonal antibody. It works by blocking the activity of two inflammatory proteins: interleukin-4 (IL-4) and interleukin-13 (IL-13). These signals contribute to inflammation seen in conditions like atopic dermatitis, asthma, COPD with eosinophilia, CRSwNP, CSU, EoE, and prurigo nodularis. By reducing these signals, Dupixent can help improve symptoms and reduce disease activity over time.
Forms and Strengths
Dupixent is a solution for subcutaneous injection supplied as:
- 300 mg/2 mL single-use pre-filled syringe or pre-filled pen
- 200 mg/1.14 mL single-use pre-filled syringe (with needle shield) or pre-filled pen
Your prescriber chooses the strength and schedule based on your condition, age, and body weight (for certain pediatric uses).
Dosing Basics (General Overview)
Dosing depends on the condition being treated. Some adult indications start with a “loading dose” (two injections on day 1) followed by a maintenance dose. Always follow your prescriber’s dosing instructions.
- COPD (adults): 300 mg every 2 weeks.
- CRSwNP (adults): 300 mg every 2 weeks.
- Prurigo nodularis (adults): initial 600 mg (two 300 mg injections), then 300 mg every 2 weeks.
- CSU (adults): initial 600 mg (two 300 mg injections), then 300 mg every 2 weeks.
- Asthma (adults/adolescents 12+ needing oral corticosteroids): initial 600 mg (two 300 mg injections), then 300 mg every 2 weeks.
- EoE (age 1+ and ≥15 kg): weight-based; some patients use 300 mg weekly (particularly at higher body weights), while others use every-2-week schedules depending on weight.
For children and teens, dosing is often based on body weight and the specific indication. If you’re purchasing from Canada to save money, it’s still important to confirm the exact regimen (including loading dose) with your prescriber so the correct quantity is dispensed.
Missed Dose Guidance
- If your schedule is every week and you miss a dose: take it as soon as possible and start a new weekly schedule based on that date.
- If your schedule is every 2 weeks and you miss a dose: give the injection within 7 days of the missed dose and continue your original schedule. If not given within 7 days, wait until the next scheduled dose.
How to Inject Dupixent (Pen or Syringe)
Dupixent is injected under the skin (subcutaneously). It is not intended for intravenous or intramuscular injection. The product monograph includes detailed “Instructions for Use” for both the pre-filled pen and the pre-filled syringe.
Before You Inject: Key Safety Checks
- Confirm you have the correct product and dose and check the expiry date.
- Inspect the solution through the viewing window: it should be clear and colorless to pale yellow. An air bubble may be present and is normal.
- Do not use if the liquid is discolored, cloudy, or has visible flakes/particles.
- Do not shake. Do not heat. Do not freeze.
Let It Warm to Room Temperature
- Allow at least 45 minutes at room temperature for certain pre-filled syringes/pens (commonly the 300 mg presentations).
- Some 200 mg pen presentations instruct a 30-minute warm-up.
- Do not speed warming with hot water, microwave, or direct sunlight.
Choose an Injection Site
- Recommended sites include the thigh or abdomen (avoid the 5 cm / 2 inches around the belly button).
- The upper arm can be used if a caregiver is giving the injection (outer upper arm area).
- Rotate injection sites each time.
- If you need a second injection to complete a loading dose, leave at least 5 cm (2 inches) between injection sites.
- Do not inject through clothes.
- Do not inject into skin that is tender, bruised, scarred, damaged, or irritated.
Pen-Specific Basics (High Level)
- Gather supplies: alcohol wipe, cotton ball/gauze, and a puncture-resistant sharps container (not included in the carton).
- Clean the skin with an alcohol wipe and let it dry.
- Remove the pen cap as instructed (do not twist if your pen instructions say to pull straight off).
- Follow the step-by-step “Give injection” sequence in your pen leaflet exactly and dispose of the pen safely after use.
Syringe-Specific Basics (High Level)
- Do not remove the needle cap until you are ready to inject.
- Do not pull back on the plunger.
- Do not try to remove air bubbles.
- After injection, the needle shield activates to cover the needle.
- Do not re-use the syringe.
Common Side Effects
Side effects can vary by the condition being treated and the individual patient. Some commonly reported side effects with Dupixent include:
- Injection site reactions (redness, swelling, discomfort)
- Eye-related effects (conjunctivitis; in some cases keratitis)
- Cold-like symptoms (depending on population studied)
- Herpes virus infections in some patient groups (including herpes zoster reported at low frequencies in prurigo nodularis studies)
Eye symptoms deserve special attention. Conjunctivitis and keratitis-related events have occurred more frequently in atopic dermatitis compared with some other indications. Patients should report new or worsening eye symptoms, including blurred vision, eye pain, or persistent redness.
Serious Side Effects and When to Get Help
Seek urgent medical care if you think you are having a serious reaction. Serious side effects may include allergic reactions, including swelling of the face/lips/mouth/throat or tongue (angioedema), trouble breathing, hives, severe rash, fainting, dizziness, or low blood pressure symptoms.
Dupixent should be stopped and medical attention sought right away if a serious systemic hypersensitivity reaction is suspected.
Important Warnings and Precautions
- Asthma/COPD: Dupixent is not used to treat acute symptoms, acute bronchospasm, or status asthmaticus. Patients should seek medical advice if asthma remains uncontrolled or worsens after starting treatment.
- Corticosteroid tapering: Do not stop systemic, topical, or inhaled corticosteroids abruptly when starting Dupixent. Any reduction should be gradual and supervised by a healthcare professional.
- Eosinophilic conditions: In asthma, cases of serious systemic eosinophilia have been reported, sometimes with eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis. Providers may monitor for vasculitic rash, worsening lung symptoms, cardiac complications, or neuropathy in patients with eosinophilia.
- Helminth infections: Treat pre-existing helminth infections before starting Dupixent. If a patient develops a helminth infection during therapy and does not respond to treatment, Dupixent may need to be stopped until the infection resolves.
- Eye inflammation: Persistent conjunctivitis or symptoms suggestive of keratitis should be assessed, and an eye examination may be needed.
- Joint symptoms: Arthralgia has been reported, and some cases included decreased mobility; patients should report new or significant joint pain.
Storage and Handling
- Store in a refrigerator at 2°C to 8°C.
- Keep in the original carton to protect from light.
- Do not freeze. Do not heat. Do not shake. Avoid direct sunlight.
- If needed, it may be kept at room temperature up to 25°C for a maximum of 14 days. If left out longer than 14 days, it should be discarded.
- Before injecting, allow it to reach room temperature naturally (time depends on presentation—follow your specific device instructions).
After use, place the syringe or pen in a puncture-resistant sharps container and follow local disposal rules. Do not place used syringes/pens in household trash unless local guidance permits disposal in an approved puncture-resistant container.
Dupixent Compared to Other Treatments
Dupixent is not a steroid and it is not a traditional immunosuppressant like older systemic agents. It is a targeted biologic that blocks IL-4 and IL-13 signaling. Depending on the condition, Dupixent may be used:
- With topical therapies (such as topical corticosteroids or topical calcineurin inhibitors for eczema)
- With inhaled controller medications for asthma or COPD maintenance therapy
- With intranasal corticosteroids for CRSwNP
- After other therapies have not provided adequate symptom control, depending on the diagnosis and severity
Your healthcare provider chooses therapy based on disease severity, previous response, comorbidities, and safety considerations.
Disclaimer
This information is for educational purposes only and does not replace medical advice. Always follow your prescriber’s instructions and the device-specific “Instructions for Use” included with your medication. Contact a healthcare professional if you have side effects, questions about dosing, or concerns about your condition.
Reference: Dupixent Product Monograph